EF Hutton initiated coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Buy rating and a price target of $304.00.The company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE